blood biomarkers

PreclinicalBiologic

QQilu Hospital of Shandong University

blood biomarkers is one of 39 biologic programs targeting Myocardial Infarction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionActive, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

2 2

Ikorel

Merck & Co.

Phase 3

2 3

Medrol

Pfizer

Phase 3

2 4

Lovenox

Sanofi

Phase 3

1 5

Eliquis

Bristol-Myers Squibb

Phase 3

1 6

Aranesp

Reopro

4 8

Zetia

OOrganon and Co

Phase 3

3 9

Jardiance

Boehringer Ingelheim

Phase 3

2 10

Aggrastat

MMedicure

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2040

Active, not recruiting

Myocardial Infarction

NCT03192410

Clinical

Trials by Indication[1]

COPD1 trial

COPD-Related Physiology and the Brain

Completed·KKarin Hoth··NCT03269721·170 enrolled

Biomarkers1 trial

Rapid Identification of MINOCA Based on Novel Biomarkers

Unknown status·QQilu Hospital of Shandong University··NCT04974320·2,616 enrolled

Myocardial Infarction1 trial

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

Active, not recruiting·WWageningen University··NCT03192410·4,837 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for blood biomarkers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — blood biomarkers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for blood biomarkers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Hospital of Shandong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: QQilu Hospital of Shandong University

blood biomarkers

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2040

Trials by Indication[1]

COPD1 trial

Biomarkers1 trial

Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News